Chinese red yeast rice versus lovastatin effects on prostate cancer cells with and without androgen receptor overexpression

Journal of Medicinal Food

Volumn 11, Issue 4, 2008, Pages 657-666

  Hong, Mee Young ^a,b   Seeram, Navindra P ^a   Zhang, Yanjun ^a   Heber, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase; Chinese red yeast rice; Cholesterogenesis; Lovastatin; Monacolins; Pigment; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; MEVINOLIN; PIGMENT; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTOR; XUEZHIKANG;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR GENE; UPREGULATION;

ANDROGENS; ANTICHOLESTEREMIC AGENTS; APOPTOSIS; BIOLOGICAL PRODUCTS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MEVALONIC ACID; MONASCUS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

MONASCUS PURPUREUS;

EID: 57349142139     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2007.0702     Document Type: Article

References (56)

1. American Cancer Society Cancer facts and figures 2007. http://www.cancer.org (accessed December 1, 2007).
2. Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS: Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006;95:767-774.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL: Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-39.
4. Kokontis JM, Hay N, Liao S: Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998;12:941-953.
5. Zhang L, Johnson M, Le KH, Sato M, Ilagan R, Iyer M, Gambhir SS, Wu L, Carey M: Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res 2003;63:4552-4560.
6. Jariwala U, Prescott J, Jia L, Barski A, Pregizer S, Cogan JP, Arasheben A, Tilley WD, Scher HI, Gerald WL, Buchanan G, Coetzee GA, Frenkel B: Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer 2007;6:39-53.
7. Kim D, Gregory CW, French FS, Smith GJ, Mohler JL: Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am J Pathol 2002;160:219-226.
8. Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, Zhang D, Cooper R, Chang M: Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000;48:5220-5225
9. Haval RJ: Dietary supplement or drug? The case of cholestin. Am J Clin Nutr 1999;69:175-176.
10. Stuart MD: Chinese Material Medica: Vegetable Kingdom. Southern Materials Center, Taipai, Republic of China, 1979.
11. Went FAFC: Monascus purpureus le champignon de l'angquac une nouvelle thelebolee. Ann Soc Nat Bot 1895;8:1-17.
12. Martinkova L, Patakova-Juzlova P, Krent V, Kucerova Z, Havlicek V, Olsovsky P, Hovorka O, Rihova B, Vesely D, Vesela D, Ulrichova J, Prikrylova V: Biological activities of oligoketide pigments of Monascus purpureus. Food Addit Contam 1999;16:15-24.
13. Heber D, Lembertas A, Lu Q-Y, Bowerman S, Go VLW: An analysis of nice proprietary Chinese Red Yeast Rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001;7:133-139.
14. Chen FC, Manchand PS, Whalley WB: The chemistry of fungi. LXIV. The structure of monascin: the relative stereochemistry of the azaphilones. J Chem Soc 1971;21:3577-3579.
15. Manchand PS, Whally WB, Chen FC: Isolation and structure of ankaflavin. Phytochemistry 1973;12:2531-2532.
16. Kuromo M, Nakanishi K, Shindo K, Tada M: Biosynthesis of monascorubrin and monascoflavin. Chem Pharm Bull (Tokyo) 1963;11:358-362.
17. Hadfield JR, Holker JSE, Stanway DN: The biosynthesis of fungal metabolites. Part II. The β-oxo-lactone equivalences in rubropunctatin and monascorubrin. J Chem Soc 1967;19:751-755.
18. Kim C, Jung H, Kim YO, Shin CS: Antimicrobial activities of amino acid derivatives of Monascus pigments. FEMS Microbiol Lett 2006;264:117-124.
19. Journoud M, Jones PJ: Red yeast rice: a new hypolipidemic drug. Life Sci 2004;74:2675-2683.
20. Yasukawa K, Takahashi M, Natori S, Kawai K, Yamazaki M, Takeuchi M, Takido M: Azaphilones inhibit tumor promotion by 12-O-tetradecanoylphorbol-13- acetate in two-stage carcinogenesis in mice. Oncology 1994;51:108-112.
21. Yasukawa K, Takahashi M, Yamanouchi S, Takido M: Inhibitory effect of oral administration of Monascus pigment on tumor promotion in two-stage carcinogenesis in mouse skin. Oncology 1996;53:247-249.
22. Hong MY, Seeram NP, Zhang Y, Heber D: Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. J Nutr Biochem 2008;19:448-458.
23. Retterstol K, Stugaard M, Gorbitz C, Ose L: Results of intensive long-term treatment of familial hypercholesterolemia. Am J Cardiol 1996;78:1369-1374.
24. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM: Statins and cancer prevention. Nat Rev Cancer 2005;5:930-942.
25. Lewis-Barned NJ, Ball MJ: Beneficial effect of simvastatin in patients with drug resistant familial hypercholesterolaemia. N Z Med J 1992;105:284-286.
26. Jenkins DJ, Kendall CS, Marchie A, Faulkner DA, Wond JM, de Souza R, Emam A, Parker TL, Vidgen E, Lapsley KG, Trautwein EA, Josse RG, Leiter LA, Connelly PW: Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003;290:502-510.
27. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL: Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-236.
28. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, Farris PE: Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-325.
29. Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko B, Adamovich E: Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005;66:1150-1154.
30. Blais L, Desgagne A, LeLorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000;160:2363-2368.
31. Marcelli M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, Denner L: Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 1998;58:76-83.
32. Padayatty SJ, Marcelli M, Shao TC, Cunningham GR: Lovastatin-induced apoptosis in prostate stromal cells. J Clin Endocrinol Metab 1997;82:1434-1439.
33. Moorman PG, Hamilton RJ: Statins and cancer risk: what do we know and where do we go from here? Epidemiology 2007;18:194-196.
34. Coogan PF, Rosenberg L, Strom BL: Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-219.
35. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S: Statin use and the risk of breast and prostate cancer. Epidemiology 2002;13:262-267.
36. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-1825.
37. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS: Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296:2351-2361.
38. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS: The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-448.
39. Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ: Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006;91:3850-3856.
40. Pelletier G, Luu-The V, El-Alfy M, Li S, Labrie F: Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J Mol Endocrinol 2001;26:11-19.
41. Cyrus-David MS, Weinberg A, Thompson T, Kadmon D: The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol 2005;173:1923-1925.
42. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959-968.
43. Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nat Rev 2001;1:34-45.
44. Gelmann EP: Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-3015.
45. Grossman ME, Huang H, Tindall DJ: Androgen receptor signaling in androgen refractory prostate cancer. J Natl Cancer Inst 2001;93:1687-1697.
46. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR, Skinner JM: Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res 1994;54:4096-4102.
47. Prins GS, Sklarew RJ, Pertschuk LP: Image analysis of androgen receptor immuno-staining in prostate cancer accurately predicts response to hormonal therapy. J Urol 1998;159:641-649.
48. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP: In vivo amplification of the androgen receptor geneand progression of human prostate cancer. Nat Genet 1995;9:401-406.
49. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS: Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450-459.
50. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H, Cato AC: Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int J Cancer 1995;63:544-550.
51. Shi X, Ma A, Xia L, Kung H, de Vere White RW: Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002;62:1496-1502.
52. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004;30:609-641.
53. Muller C, Kiehl MG, van de Loo J, Koch OM: Lovastatin induces p21WAF1/Cip1 in human vascular smooth muscle cells: influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition. Int J Mol Med 1999;3:63-68.
54. Ahn KS, Sethi G, Aggarwal BB: Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J Immunol 2007;178:2507-2516.
55. Mantha AJ, Hanson JEL, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J: Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 2005;11:2398-2407.
56. Hong MY, Seeram NP, Heber D: Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. J Nutr Biochem 2008 May 12 [Epub ahead of print].